Adaptive Biotechnologies stock hits 52-week high at $15.29

Adaptive Biotechnologies Corp stock (market cap: $2.3 billion) reached a 52-week high of $15.29, marking a significant milestone for the company. According to InvestingPro data, the stock is currently trading above its Fair Value. Over the past year, the stock has experienced a remarkable 173% increase, with particularly strong momentum showing an 87% gain in the last six months. The company maintains a healthy financial position with a current ratio of 2.84, though analysts don’t expect profitability this year. This surge underscores the company’s growth trajectory and potential in the biotechnology sector. The 52-week high achievement is a testament to Adaptive Biotechnologies’ strategic initiatives and market positioning, as it continues to advance its innovative solutions in the field of immune-driven medicine. For deeper insights into ADPT’s valuation and growth prospects, access the comprehensive Pro Research Report available on InvestingPro.

In other recent news, Adeptus Biotechnologies Corp. announced the termination of its collaboration and license agreement with Genentech, effective February 9, 2026. This decision will release Adeptus from exclusivity obligations related to cell therapies in oncology, allowing the company to explore new licensing deals with other biopharmaceutical firms. Following this development, BTIG reiterated its Buy rating for Adeptus, maintaining a $14.00 price target. Piper Sandler raised its price target for Adeptus to $15.00, citing a promising growth outlook, particularly in the company’s Minimal Residual Disease (MRD) business, which is expected to sustain a 30% revenue growth rate. Morgan Stanley also increased its price target to $11.00, highlighting strong performance in the company’s clonoSEQ volume and average selling price. Additionally, BTIG raised its price target from $13.00 to $14.00, following Adeptus’ strong second-quarter earnings that surpassed expectations. The company achieved adjusted EBITDA positivity in its MRD business ahead of schedule, prompting an upward revision of its annual guidance. These developments reflect the company’s ongoing momentum and strategic shifts in its business operations.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.